Identity
- Security key
- 22161
- Ticker
- STTK
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2020-10-09
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- STTK
Detail
Enriched 2026-08-14 20:47
- Market cap
- $751,720,764.97
- Shares outstanding (class)
- 76,680,517
- Shares outstanding (weighted)
- 100,363,253
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 40
- Location
- AUSTIN, TX
- Homepage
- https://www.shattucklabs.com
- Description
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.